Changes of HBV Markers in Serum and Liver Tissue in Patients with Chronic Hepatitis B Treated with Recombinant Alpha-Interferon (rIFN-α): Results of a Controlled Study
| Autor: | R. Moschetta, Teresa Santantonio, D. Maladorno, D. Criscuolo, E. Sforza, Michele Milella, Laura Monno, G. Pastore |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
0301 basic medicine
HBsAg Cirrhosis 030106 microbiology medicine.disease_cause 01 natural sciences 03 medical and health sciences Liver disease medicine Interferon alfa Hepatitis B virus biology business.industry virus diseases General Medicine medicine.disease biology.organism_classification digestive system diseases 0104 chemical sciences 010404 medicinal & biomolecular chemistry HBcAg HBeAg Hepadnaviridae Immunology business medicine.drug |
| Zdroj: | Antiviral Chemistry and Chemotherapy. 1:329-331 |
| ISSN: | 2040-2066 |
| DOI: | 10.1177/095632029000100508 |
| Popis: | In the natural history of chronic hepatitis type B, spontaneous cessation of hepatitis B virus (HBV) replication, characterized by the disappearance of serum HBeAg and HBV DNA and intrahepatic HBcAg, is usually associated with remission of liver disease. However, in some patients this event occurs late, when the liver damage, closely related to continuous HBV replication, has already progressed to cirrhosis, portal hypertension and hepatic failure (Pastore et al., 1977; Realdi et al., 1980). Attempts to increase the rate of spontaneous cessation of viral replication or complete clearance of HBV have been made using different antiviral agents, including interferon (IFN)-alpha and beta (Dooley et al., 1986; Hoofnagle et al., 1988; Saracco et et., 1989; Eisenberg et sl., 1986). In this study we evaluated the efficacy of a low dosage of recombinant IFN-u (rIFN-u) in a randomized controlled study of adult patients with HBsAg and HBeAg positive chronic hepatitis. Thirty heterosexual HBsAg chronic carriers, aged 18-55 years, were admitted to the study and randomly allocated to receive rlFN-u (14 patients) or no treatment (16 patients). All patients fulfilled the following criteria: presence of serum HBsAg, HBeAg and HBV DNA for at least 1 year, raised serum alanine, absence of serological markers for hepatitis delta virus (HDV) and human immunodeficiency virus (HIV), no history or other evidence of alcohol and intravenous drug abuse, and no previous therapy with antiviral drugs or corticosteroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|